Manufacturer
79 recalls in our database name SUN PHARMACEUTICAL INDUSTRIES INC as the manufacturing or recalling firm.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
SUN PHARMACEUTICAL is recalling Fluocinonide 0.05% Cream nationwide due to viscosity exceeding specification limits discovered during stability testing.
SUN PHARMACEUTICAL is recalling Fluocinonide cream (0.05%) due to out-of-specification viscosity levels found during stability testing. The affected product was distributed nationwide.
SUN Pharmaceutical is recalling 24,672 tubes of Fluocinonide 0.05% cream (Lot AD76252) distributed nationwide due to viscosity test failures discovered during stability testing.
SUN PHARMACEUTICAL is recalling Diclofenac Sodium Topical Gel (3% in 100 g tubes) due to viscosity specification failure. Lot AD92721 (expires 3/31/2027) was distributed nationwide.
SUN Pharmaceutical recalls Clindamycin Phosphate 1% topical solution nationwide due to failed quality control tests showing out-of-specification impurities and assay results. Affected lots should be discontinued.
Sun Pharmaceutical is recalling Fluocinolone Acetonide Solution topical solution distributed nationwide due to manufacturing quality issues. Testing found an impurity level that exceeded specifications.
Sun Pharmaceutical Industries is recalling specific lots of Lisdexamfetamine Dimesylate capsules because they failed dissolution testing during stability analysis. The affected lots may not dissolve properly to deliver the intended dose.
Sun Pharmaceutical is recalling Lisdexamfetamine Dimesylate 60 mg capsules (Lots AD48711 and AD50896) distributed nationwide due to failed dissolution specifications identified in stability testing. The affected capsules may not dissolve properly.
Sun Pharmaceutical recalls Lisdexamfetamine Dimesylate 30 mg capsules nationwide due to failed dissolution test results during 12-month stability testing. No illnesses have been reported.
Sun Pharmaceutical is recalling specific lots of Lisdexamfetamine Dimesylate Capsules 50 mg due to failed dissolution specifications that may affect medication effectiveness.
Sun Pharmaceutical is recalling specific lots of Lisdexamfetamine Dimesylate 70 mg capsules nationwide due to failed dissolution test results detected during stability testing.
Sun Pharmaceutical Industries is recalling Lisdexamfetamine Dimesylate capsules nationwide due to failed dissolution specifications discovered during stability testing. No illnesses have been reported.
Sun Pharmaceutical is recalling specific lots of Lisdexamfetamine Dimesylate capsules nationwide because dissolution test results fell outside specifications during stability testing.
Sun Pharmaceutical recalls 1870 kits of Technetium Tc99m Mertiatide due to failed dissolution specifications in a component used for production. The affected lot was distributed nationwide.
Sun Pharmaceutical is recalling Spironolactone tablets nationwide due to the presence of aluminum, a foreign substance. Patients should consult their healthcare provider before making changes to treatment.
Sun Pharmaceutical is recalling 5,448 bottles of Lisdexamfetamine Dimesylate 60mg capsules due to failed dissolution specifications detected during long-term stability testing. No illnesses have been reported.
Sun Pharmaceutical is voluntarily recalling 852 bottles of Gabapentin 400mg capsules nationwide due to cross contamination. The recall affects Lot HAD1712B and HAD1712C, both expiring March 2025.
Sun Pharmaceutical is recalling 12,876 bottles of Gabapentin 300 mg capsules distributed nationwide due to cross contamination. The recall is voluntary and ongoing.
Sun Pharmaceutical is recalling Morphine Sulfate Extended-Release 100 mg tablets (lot AD16615) because they fail dissolution specifications, potentially resulting in unpredictable drug delivery.
Sun Pharmaceutical recalls Nitrofurantoin Capsules (100 mg) due to failed dissolution, affecting medication effectiveness. The recall involves 5,752 bottles nationwide in lots 231067 and 231069.
Sun Pharmaceutical is recalling Decitabine for Injection (lot HAD2964A, 2,088 vials) for a Current Good Manufacturing Practice deviation. The Total Aerobic Microbial Count test on unfiltered bulk was out of specification; the product was distributed nationwide.
Sun Pharmaceutical recalls Xelpros latanoprost eye drops (Lot HAD3383A) due to particulate matter contamination detected during release testing. Affected bottles were distributed in Texas and Pennsylvania.
Sun Pharmaceutical is recalling Amphotericin B for Injection (50 mg vials) due to out-of-specification assay results. The recall affects 11,016 vials with lot numbers BAE0055A, BAE0056A, and BAE0068A distributed nationwide.
Sun Pharmaceutical is recalling 47,520 bottles of Febuxostat 40mg tablets nationwide due to microbial contamination found in manufacturing equipment. The FDA classified this as a Class II recall; no illnesses have been reported.
Sun Pharmaceutical is recalling 7,488 bottles of Febuxostat 80mg tablets nationwide due to microbial contamination found in manufacturing equipment. No illnesses have been reported.